Want to see EQ full AI Analyst Report?
EQ Stock Chart & Stats
$2.05
-$0.05(-6.85%)
At close: 4:00 PM EST
$2.05
-$0.05(-6.85%)
Day’s Range― - ―
52-Week Range$0.36 - $3.54
Previous CloseN/A
Volume484.47K
Average Volume (3M)830.80K
Market Cap
$163.76M
Enterprise Value$131.93
Total Cash (Recent Filing)$61.32M
Total Debt (Recent Filing)$692.00K
Price to Earnings (P/E)―
Beta-0.04
Next Earnings
Aug 12, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding63,226,555
10 Day Avg. Volume953,216
30 Day Avg. Volume830,804
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.98
Price to Sales (P/S)0.00
P/FCF Ratio-6.25
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside339.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.23
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageExtremely low debt reduces solvency and interest-rate risk, giving management flexibility to prioritize R&D and clinical programs without large fixed financing costs. For a clinical-stage biotech, minimal leverage materially improves runway management and lowers bankruptcy risk while pursuing partnerships.
Recent $35M Financing Strengthens RunwayA sizable private placement provides durable near-term liquidity to advance clinical-stage programs (EQ504) and reduces immediate refinancing pressure. This funding supports milestone-driven development and increases the probability of reaching de-risking clinical readouts or partnering opportunities within the next several quarters.
Focused Immunology PipelineA clear focus on targeted immunomodulatory biologics and T-cell pathway modulation gives strategic coherence and potential clinical differentiation. Multiple assets across stages diversify development risk and increase options for licensing, partnerships, or staged value realization as programs reach clinical inflection points.
Bears Say
Near-zero Revenue And Persistent LossesThe collapse to near-zero revenue and recurring operating losses mean the company cannot self-fund development from product cash flow. This structural gap forces ongoing financing, reduces bargaining power with partners, and lengthens the timeline to positive returns until a commercial product or material partnership is secured.
Heavy Cash Burn And Funding DependenceConsistent negative operating and free cash flow aligns with net losses and indicates development is funded externally. Sustained cash burn increases dilution risk, can force program prioritization or delay, and makes strategic planning contingent on unpredictable financing or milestone payments rather than recurring revenue.
Capital Structure & Governance Changes Raise Dilution RiskAuthorization to expand shares and execute reverse splits grants management flexibility to raise capital or adjust trading metrics but also signals likely future equity issuance. This structural capacity increases dilution risk and creates long-term ownership uncertainty, which can hinder investor confidence and partnership terms.
Equillium News
EQ FAQ
What was Equillium’s price range in the past 12 months?
Equillium lowest stock price was $0.36 and its highest was $3.54 in the past 12 months.
What is Equillium’s market cap?
Equillium’s market cap is $163.76M.
When is Equillium’s upcoming earnings report date?
Equillium’s upcoming earnings report date is Aug 12, 2026 which is in 22 days.
How were Equillium’s earnings last quarter?
Equillium released its earnings results on May 13, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.046 by -$0.014.
Is Equillium overvalued?
According to Wall Street analysts Equillium’s price is currently Undervalued.
Does Equillium pay dividends?
Equillium does not currently pay dividends.
What is Equillium’s EPS estimate?
Equillium’s EPS estimate is -0.05.
How many shares outstanding does Equillium have?
Equillium has 63,226,555 shares outstanding.
What happened to Equillium’s price movement after its last earnings report?
Equillium reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.046. Following the earnings report the stock price went up 12.121%.
Which hedge fund is a major shareholder of Equillium?
Currently, no hedge funds are holding shares in EQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Equillium Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (339.02% Upside)
$9.00 (339.02% Upside)
Blogger Sentiment
Bullish
EQ Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $723.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
515.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
277.09%
Trailing 12-Months
Company Description
Equillium
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
EQ Stock 12 Month Forecast
Average Price Target
$9.00
▲(339.02% Upside)
Technical Analysis
Ownership Overview
13.05% Insiders
3.30% Mutual Funds
38.11% Other Institutional Investors
42.38% Public Companies and
Individual Investors